Skip to content
value.today

Ensho Therapeutics, Inc.

🇺🇸 Morris Plains, New York, USABiotechnologyFounded 2024
Total raised
$12 M
2 rounds on record
Latest round
$7 M
Oct 2026
First round on record
Oct 2024
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ensho Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$7 MNo. 2$2 to $10 million

Ensho Therapeutics, Inc.: Raise no. 2, Oct 2026

Investors in this round

7 investors had bought by the notice of Oct 15, 2026: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $16 M offered; $8 M still to sell
Smallest investment taken
$1
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Danielle Fry · Executive Officer
  • Arash Rassoulpour · Director
  • Carlos Solorzano · Director
  • Eric Pham · Director
  • Gerhard Hagn · Director
  • Neena Bitritto-Garg · Director
  • Tariq Kassum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Danielle Fry, Chief Legal Officer & Chief Operating Officer. Newest notice filed Oct 15, 2026. Read the notice at the SEC.

equitySEC
Oct 2024$5 MNo. 1$2 to $10 million

Ensho Therapeutics, Inc.: Raise no. 1, Oct 2024

Investors in this round

1 investor had bought by the notice of Nov 12, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $13 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bittoo Kanwar · Executive Officer
  • Danielle Andrew Fry · Executive Officer
  • Emily Andrew Weng · Executive Officer
  • James Andrew Whitney · Executive Officer
  • Matthew Andrew McKevitt · Executive Officer
  • Neena Bitritto-Garg · Executive Officer, Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Neena Bitritto-Garg, President and CEO. Newest notice filed Nov 12, 2024. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ensho Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ensho Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ensho Therapeutics, Inc.
NameRoleNamed in
Danielle FryExecutive officerOct 2026
Bittoo KanwarExecutive officerNov 2024
Danielle Andrew FryExecutive officerNov 2024
Emily Andrew WengExecutive officerNov 2024
James Andrew WhitneyExecutive officerNov 2024
Matthew Andrew McKevittExecutive officerNov 2024
Neena Bitritto-GargExecutive officerNov 2024
Arash RassoulpourDirectorOct 2026
Carlos SolorzanoDirectorOct 2026
Eric PhamDirectorOct 2026
Gerhard HagnDirectorOct 2026
Neena Bitritto-GargDirectorOct 2026
Tariq KassumDirectorOct 2026
Neena Bitritto-GargPromoterNov 2024